HLAA will convene and host a Patient-Focused Drug Development (PFDD) meeting with permission from the Food and Drug Administration (FDA) on sensorineural hearing loss and its impact on daily life. All are welcome to attend. This session will be free and open to all. Look for more information to come. We will also hold an HLAA webinar on Thursday, April 8, 2021, 2-3 p.m. ET to let you know what to expect and how to participate in the PFDD meeting in May.

Patient-Focused Drug Development (PFDD) meetings were first started by the FDA to try and find a better way to hear directly from patients, their caregivers and families. The meetings explore what symptoms matter most to them, the impacts on patients’ daily lives, and patients’ experiences with currently available treatments. This information helps the FDA both during drug development as well as during review of marketing applications for new drugs.

It is exciting that HLAA can lead the charge here with the FDA who will attend and listen. Our hope is that patient engagement through a PFDD will go a long way in shaping future hearing loss treatments and creating a deeper understanding of the impact of hearing loss on individuals, their quality of life and associated comorbidities.

Your Organization Can Participate

Show the FDA you are an advocacy group or any organization who cares about research and therapies for hearing loss. If you would like to be involved in this PFDD by having your name and logo attached to the meeting, the recorded webinar meeting and the Voice of the Patient report, please email Carrie Johnson, director of communications, regarding free partnership opportunities.